Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Vascular Biogenics Ltd. (Vbl Therapeutics)
Headquarters: Modiin, Israel
Website: N/A
Year Founded: 2000
Status: Reverse-merged
BioCentury | Apr 20, 2022
Data Byte
The Phase III pipeline for ovarian cancer
Companies are testing 15 therapies across four mechanisms; five trials to report data this year
BioCentury | Oct 5, 2021
Management Tracks
Medicxi’s Grainger joins Centessa as chief innovation officer
Plus: Certara, MOMA, Quotient, Mogrify, Acadia, CorMedix and more
BioCentury | Jan 18, 2020
Product Development
Mapping the path to gene therapy 2.0
Getting to gene therapy 2.0 will require improvements under way, plus an overhaul of manufacturing strategy
BioCentury | Oct 15, 2018
Preclinical News
mAb blocks fibrin's inflammation without clotting interference to treat MS, Alzheimer's
BioCentury | Jan 5, 2018
Clinical News
VBL begins Phase III of gene therapy VB-111 to treat ovarian cancer
BioCentury | Nov 10, 2017
Company News
VBL grants NanoCarrier Japanese rights to GBM gene therapy VB-111
Items per page:
1 - 10 of 20